Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Introduction & Market Context
International Flavors & Fragrances Inc (NYSE:IFF) reported its first quarter 2025 results on May 7, showing a mixed performance with declining reported revenue but improved profitability metrics. The company’s stock closed at $79.20 on May 6, with premarket trading indicating a decline of 0.86% to $78.52 ahead of the earnings call.
The results come as IFF continues to navigate macroeconomic uncertainties, supply chain cost increases, and potential tariff impacts. Despite these challenges, the company maintained its full-year guidance, emphasizing its focus on customer collaboration and productivity initiatives.
Quarterly Performance Highlights
IFF reported Q1 2025 revenue of $2.84 billion, representing a 2% decrease from the $2.90 billion reported in Q1 2024. However, on a comparable currency neutral basis, sales increased by 3%, indicating that currency headwinds and portfolio changes significantly impacted the reported figures.
As shown in the following consolidated results:
Adjusted Operating EBITDA remained flat year-over-year at $578 million but increased by 9% on a comparable currency neutral adjusted basis. The company’s profitability showed improvement, with Adjusted Operating EBITDA margin expanding to 20.3% from 19.9% in the prior year, representing a 40 basis point improvement or 120 basis points on a comparable currency neutral adjusted basis.
This performance marks a slight deceleration from Q4 2024, when the company reported a 6% comparable currency-neutral revenue growth, though margin improvement has continued.
Segment Analysis
IFF’s business segments showed divergent performance in the first quarter, with strong growth in several divisions offset by weakness in Food Ingredients.
The segment breakdown reveals the varied performance across IFF’s portfolio:
The Taste segment delivered the strongest performance with a 7% increase in net sales to $627 million and an impressive 22% growth in Adjusted Operating EBITDA to $131 million, highlighting robust performance in Flavors.
Food Ingredients was the only segment to report a sales decline, with net sales decreasing by 4% to $796 million, though its Adjusted Operating EBITDA still increased by 5% to $111 million.
Health & Biosciences showed solid growth with net sales increasing 5% to $540 million and Adjusted Operating EBITDA rising 3% to $138 million.
The Scent segment reported consistent growth with net sales and Adjusted Operating EBITDA both increasing by 4% to $614 million and $144 million respectively, driven by strength in Fine Fragrance and Consumer Fragrances.
Pharma Solutions demonstrated strong performance with net sales increasing 8% to $266 million and Adjusted Operating EBITDA growing 19% to $54 million, prior to its divestiture.
The currency impact on each segment’s performance is detailed in the following breakdown:
Cash Flow and Debt Position
IFF’s cash flow and leverage metrics for Q1 2025 showed some pressure on short-term liquidity while making progress on its debt reduction goals.
The company’s cash flow details are illustrated below:
Cash flow from operations totaled $127 million in Q1, while capital expenditures reached $179 million (approximately 6% of sales), resulting in a negative free cash flow of $52 million for the quarter. The company paid $102 million in dividends during the period.
IFF ended the quarter with $650 million in cash and cash equivalents, including $37 million held for sale. Gross debt stood at $9,319 million, with a trailing 12-month credit adjusted EBITDA of $2,207 million, resulting in a net debt to credit adjusted EBITDA ratio of 3.9x.
This represents a slight regression from the 3.8x reported at the end of Q4 2024, though the company highlighted that the completion of the Pharma Solutions divestiture ahead of schedule has helped achieve a net debt to credit adjusted EBITDA ratio of less than 3x.
Full-Year Outlook
Despite the macroeconomic uncertainties, IFF maintained its full-year 2025 guidance, projecting revenue between $10.6 billion and $10.9 billion, representing a 1% to 4% increase on a comparable currency neutral basis.
The detailed outlook is presented in the following chart:
The company expects Adjusted EBITDA to range between $2.0 billion and $2.15 billion, a 5% to 10% increase on a comparable currency neutral basis. Both revenue and EBITDA projections factor in a negative impact from foreign exchange (2% and 3% respectively) and from divestitures (7% and 8% respectively).
Management acknowledged increasing macroeconomic uncertainty and supply chain cost increases but emphasized their focus on controllable factors, including customer collaboration and productivity initiatives.
Strategic Initiatives
IFF’s strategic focus remains on strengthening its financial position while investing for future growth. The company highlighted several key initiatives in its presentation:
The completion of the Pharma Solutions divestiture ahead of schedule has been a significant achievement, helping the company reach its target of reducing the net debt to credit adjusted EBITDA ratio to less than 3x.
As summarized in the company’s key takeaways:
IFF continues to reinvest in research and development, commercial capabilities, and capital expenditures to drive long-term growth. The company emphasized its resilience amid economic uncertainty, focusing on innovation and "winning in the marketplace."
Management is actively working with customers to mitigate the impact of tariffs, demonstrating the company’s proactive approach to navigating trade challenges.
These strategic initiatives align with CEO Erik Fyrwald’s previous statements from the Q4 2024 earnings call, where he expressed confidence in the company’s trajectory, noting that IFF is "much stronger than we were a year ago" and committed to delivering on its 2025 promises.
As IFF progresses through 2025, investors will be watching closely to see if the company can maintain its margin improvements while returning to more robust top-line growth across all segments.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.